<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In an attempt to identify novel diagnostic markers for mast cell (MC)-proliferative disorders, serial bone marrow (bm) sections of 22 patients with <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (systemic indolent <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, n = 19; mast cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>], n = 1; isolated bm <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, n = 2) were analyzed by immunohistochemistry using antibodies against CD2, CD15, CD29, CD30, CD31, CD34, CD45, CD51, CD56, CD68R, CD117, HLA-DR, bcl-2, bcl-x(L), myeloperoxidase (MPO), and tryptase </plain></SENT>
<SENT sid="1" pm="."><plain>Staining results revealed expression of bcl-x(L), CD68R, and tryptase in neoplastic MCs (focal dense infiltrates) in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0100495'>Mastocytosis</z:hpo> infiltrates were also immunoreactive for CD45, CD117 (Kit), and HLA-DR </plain></SENT>
<SENT sid="3" pm="."><plain>In most cases, the CD2 antibody produced reactivity with bm MCs in <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, whereas in control cases (reactive bm, <z:e sem="disease" ids="C0242647,C0334633" disease_type="Neoplastic Process" abbrv="">immunocytoma</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>), MCs were consistently CD2 negative </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of bcl-2 was detectable in a subset of MCs in the patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, whereas no reactivity was seen in patients with SIM or bm <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0100495'>Mastocytosis</z:hpo> infiltrates did not react with antibodies against CD15, CD30, CD31, CD34, or MPO </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, our data confirm the diagnostic value of staining for tryptase, Kit, and CD68R in <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Apart from these, CD2 may be a novel useful marker because MCs in <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> frequently express this antigen, whereas MCs in other pathologic conditions are CD2 negative </plain></SENT>
</text></document>